Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent 120 Million Private Placement
| ELYMDelisted Stock | USD 3.09 0.06 1.90% |
About 60% of Eliem Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Eliem Therapeutics suggests that many traders are alarmed regarding Eliem Therapeutics' prospects. Eliem Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Eliem Therapeutics. Many technical investors use Eliem Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Eliem |
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately 210 million of cash and cash equivalents, including 120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Co
Read at finance.yahoo.com
 |
Eliem Therapeutics Fundamental Analysis
We analyze Eliem Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eliem Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eliem Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Eliem Therapeutics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Eliem Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eliem Therapeutics stock to make a market-neutral strategy. Peer analysis of Eliem Therapeutics could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics with similar companies.
Peers
Eliem Therapeutics Related Equities
| PHVS | Pharvaris | 6.07 | ||||
| PMVP | Pmv Pharmaceuticals | 3.82 | ||||
| ACRV | Acrivon Therapeutics, | 3.63 | ||||
| PEPG | PepGen | 1.94 | ||||
| IPSC | Century Therapeutics | 0.79 | ||||
| AVTE | Aerovate Therapeutics | 1.54 | ||||
| MOLN | Molecular Partners | 2.13 | ||||
| ADAG | Adagene | 2.36 | ||||
| HCWB | HCW Biologics | 2.50 | ||||
| ANTX | AN2 Therapeutics | 2.58 | ||||
| MNOV | MediciNova | 3.98 | ||||
| CSBR | Champions Oncology | 5.65 | ||||
| RZLT | Rezolute | 7.47 | ||||
| STTK | Shattuck Labs | 10.53 | ||||
| ANEB | Anebulo Pharmaceuticals | 10.83 |
Check out Eliem Therapeutics Hype Analysis, Eliem Therapeutics Correlation and Eliem Therapeutics Performance. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |